Cruz-Contreras DG

Language: Spanish
References: 20
Page: 256-261
PDF size: 405.50 Kb.

ABSTRACT

Antiphospolipid antibodies syndrome (AAS) is an antibodies mediated procoagulant disease that can be primary or secondary to some other rheumatic o malignant disease. The implicated antibodies are anti-β2glycoprotein-1, anticardiolipins IgG and IgM and lupic antico-agulant. The hallmark of this disease is recurrent venoarterial thromboembolic events. Sapporo’s criteria (revised in 2006) were created to establish the diagnosis, these are clinical and laboratory criteria. Treatment is moderate anticoagulation with vitamin K antagonist, the INR objective is 2.5. In pregnant cases we can use platelet antiaggregation (Aspirin) plus low molecular weight heparin. Nowadays there are some ongoing clinical controlled trail to define the use of the new oral anticoagulant agents in this disease. At this moment there is not enough evidence about the primary prophylaxis in patients with antiphospolipid antibodies syndrome, but with no thrombosis yet.

REFERENCES

1. Lim W. Antiphospholipid antibody syndrome. Am Soc Hematol Educ Program 2009;233-239.

2. Ortel TL. Thrombosis and the antiphospholipid syndrome. Am Soc Hematol Educ Program 2005;462-468.

3. Wilson WA, Gharavia AE, Koike TE, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-1311.

4. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.

5. Brand JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-1190.

6. Cuadrado MJ, Mujic F, Muñoz E, et al. Thrombocytopenia in the antiphospholipid syndrome. Ann Rheum Dis 1997;56:194-196.

7. Cambell AL, Pieangeli SS, Wellhausen S, et al. Comparison of the effects of the cardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995;73:529-534.

8. Pierangeli SS, Chen PP, Raschi E, et al. Antiphospholipid antibodies and antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 2008;34:236-250.

9. Wahl DG, Guillemin F, de Maistr E, et al. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998;7:15-22.

10. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-1832.

11. Rand JH, Wu XX, Quinn AS, Taatjes DJ. Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome. Lupus 2008;17:922-930.

12. Schulman S, Svenungsson E, Granqvist S, et al. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998;104:332-338.

13. Crowther MA, Ginsberg JS, Julian J, et al. A comparision of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Eng J Med 2003;349:1133-1138.

14. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005;3:848-853.

15. Kearon C, Akl EA, Camerota AJ, et al. Antithrombotic therapy for VTE disease. Antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physician Evidence-Based Clinical Practice Guidelines 2012. Chest 2012;141:419-449.

16. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-907.

17. Levine S, Brey R, Tilley B, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004;291:576-584.

18. Halkes P, van Gijn J, Kappelle L, et al. Medium intensity oral anticoagulants versus Aspirin after cerebral ischaemia of arterial origin (ESPIRIT): a randomized controlled trial. Lancet Neurol 2007;6:115-124.

19. The US Food and Drug Administration expansion of the approved us of Xarelto (Rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk the recurrent DVT and PE following initial treatment. Disponible en: http://www.fda.gov/NewsEvent/ Newroom/PressAnnouncements/ucm326654.htm (November 2012, accessed 31 October 2014).

20. Cohen H, Dorè CJ, Clawson S, et al. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized, controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus 2015;24:1087-1094.